TLDR:
– Venture Fund X. L.P. Atlas sold 42,302 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) stock.
– The major shareholder sold the shares at an average price of $42.85.
In a recent transaction, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) stock. The insider sold the shares at an average price of $42.85, amounting to a total value of $1,812,640.70. Following the sale, the insider now directly holds 4,925,812 shares in the company, valued at $211,071,044.20.
Kymera Therapeutics, Inc. has a market capitalization of $2.41 billion and its shares opened at $39.51 on Friday. Analysts have given a consensus rating of “Moderate Buy” to the stock with an average price target of $39.89. The company has been focusing on developing novel small molecule therapeutics that selectively degrade disease-causing proteins by utilizing the body’s natural protein degradation system.
Several institutional investors have recently bought and sold shares of Kymera Therapeutics in the market. The company is actively engaged in various clinical trials for the treatment of immunology-inflammation diseases, hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis.
